Douglas F Kling sold $2.0M of NewAmsterdam Pharma (NAMS)

Executed Jul 15 2025, disclosed Jul 17 2025, 2 days later.

Value, as filed

$2.0M

95,068 sh across 2 lots

Executed

Jul 15 2025

the trade date, as filed

Disclosed

Jul 17 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Douglas F Kling Chief Operating Officer profile →

Douglas F Kling (Chief Operating Officer) filed 9 Form 4 reports in the past 24 months (0 purchases, 9 sales), most often in NewAmsterdam Pharma Company N.V. (NAMS). The largest single filing was $2.9M of NAMS (129,559 sh across 4 lots, as filed), executed Jan 27 2025.

The name

NAMS

NewAmsterdam Pharma Company N.V. NAMS · Healthcare · 45 filings in 24 months ticker →

Healthcare · NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with ca…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Douglas F Kling in NAMS

NAMSSALE NewAmsterdam Pharma Company N.V. $1.9M
100,000 sh across 2 lots
Exec Jun 16 2025
Filed Jun 18 2025 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $1.9M
as filed
Exec May 15 2025
Filed May 19 2025 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $1.6M
as filed
Exec Apr 15 2025
Filed Apr 17 2025 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $373K
as filed
Exec Mar 26 2025
Filed Mar 28 2025 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $2.3M
as filed
Exec Mar 17 2025
Filed Mar 19 2025 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $2.0M
100,000 sh across 2 lots
Exec Feb 18 2025
Filed Feb 20 2025 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $1.5M
70,441 sh across 3 lots
Exec Jan 29 2025
Filed Jan 31 2025 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $2.9M
129,559 sh across 4 lots
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET